XERS
Xeris Biopharma Holdings, Inc.
$7.45
-0.22
(-2.87%)
Mkt Cap
1.29B
Volume
1,598,308
52W Range
5.25-10.08
Sector
Healthcare
Beta
0.85
EPS (TTM)
-0.10 USD
P/E Ratio
2242.86
Revenue (TTM)
335.41M USD
Rev Growth (5Y)
+70.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$19.07
Undervalued
strong signal
60.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
High-Growth Software
30.0 / 100 pillar composite (overridden)
Fast-growing software, still scaling up — graded A–F vs. similar companies.
Company Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M | 20.43M | 2.72M | 2.46M | 1.56M | 1.07M |
| Net Income | 554,000 | (54.84M) | (62.26M) | (94.66M) | (122.72M) | (91.14M) | (125.58M) | (60.08M) | (26.55M) | (13.21M) |
| EPS | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | -3.49 | -4.99 | -13.09 | -7.17 |
| Free Cash Flow | 27.93M | (37.85M) | (49.29M) | (103.42M) | (96.62M) | (80.94M) | (80.94M) | (57.79M) | (25.36M) | (16.12M) |
| FCF / Share | 0.17 | -0.26 | -0.36 | -0.76 | -1.22 | -1.90 | -3.10 | -4.80 | -12.51 | -8.75 |
| Operating CF | 28.63M | (36.98M) | (47.02M) | (102.89M) | (95.53M) | (80.56M) | (80.56M) | (56.28M) | (24.66M) | (16.09M) |
| Total Assets | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M | 159.15M | 108.99M | 120.03M | 45.00M | 33.53M |
| Total Debt | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M | 87.02M | 58.30M | 31.89M | 0 | 0 |
| Cash & Equiv | 111.04M | 71.62M | 67.45M | 121.97M | 67.27M | 37.60M | 19.52M | 45.72M | 42.05M | 32.27M |
| Book Value | 13.69M | (29.61M) | (6.78M) | 45.19M | 95.23M | 33.76M | 14.44M | 75.41M | (57.83M) | (31.93M) |
| Return on Equity | 0.04 | N/A | N/A | -2.09 | -1.29 | -2.70 | -8.70 | -0.80 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.10M | 83.13M | 85.81M | 74.38M | 71.54M | 60.12M | 60.10M | 54.27M | 48.06M | 40.64M | 44.39M | 48.32M |
| Net Income | (31.10M) | 2.23M | 11.08M | 621,000 | (1.93M) | (9.22M) | (5.11M) | (15.74M) | (15.01M) | (18.98M) | (13.39M) | (12.19M) |
| EPS | -0.18 | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 | -0.09 |
| Free Cash Flow | 8.05M | 9.54M | 19.71M | 18.07M | (97,000) | (10.04M) | 1.75M | (8.39M) | (10.74M) | (20.47M) | 6.15M | (14.96M) |
| FCF / Share | 0.05 | 0.06 | 0.12 | 0.10 | -0.00 | -0.07 | 0.01 | -0.06 | -0.07 | -0.15 | 0.04 | -0.11 |
| Operating CF | 8.26M | 9.87M | 20.04M | 18.43M | 182,000 | (10.03M) | 1.98M | (8.30M) | (10.35M) | (20.30M) | 6.29M | (14.61M) |
| Total Assets | 411.90M | 392.01M | 383.53M | 370.19M | 334.69M | 315.45M | 323.06M | 321.10M | 331.73M | 336.62M | 322.60M | 327.78M |
| Total Debt | 289.44M | 37.33M | 37.76M | 38.19M | 257.22M | 268.75M | 271.45M | 270.96M | 269.80M | 268.69M | 229.19M | 227.94M |
| Cash & Equiv | 121.75M | 111.75M | 111.04M | 91.60M | 59.28M | 58.44M | 71.62M | 59.23M | 57.60M | 62.69M | 67.45M | 46.14M |
| Book Value | (9.73M) | 13.01M | 13.69M | (861,000) | (19.30M) | (35.13M) | (29.61M) | (28.32M) | (19.29M) | (9.18M) | (6.78M) | 3.87M |
| Return on Equity | N/A | 0.17 | 0.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -3.15 |
XERS News
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdings, Inc. $XERS
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Brokerages
Xeris Announces Details for XP-8121 Program Overview Webinar
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics